Circulating spexins in children with obesity: relation to cardiometabolic risk

Salah, Nouran Yousef; Zeid, Dina Abu; Sabry, Rania N.; Fahmy, Reham F.; El, Mona A.; Awadallah, Eman; Omran, Azza; Gendy, Yasmin Gamal El

doi:10.1038/s41430-021-00912-7

Cited by 4 publications

(3 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As regard to gender in our study, about 66.7% (20) of obese children were female and 33.3% (10) males with Female: male ratio = 2:1. Similarly, Allam and Hamed et al [9,10] while El-Shafie et al [11] and Salah et al [12] studies showed that prevalence of obesity higher in boys than girls.…”

Section: Discussionmentioning

confidence: 87%

Selenoprotein-p as Biomarker of Selenium Status in Obese Children and Adolescents

Mahmoud,

Elshafiey,

Elsharaby

et al. 2023

AJPR

View full text Add to dashboard Cite

Background: The child and adolescent obesity have become a major public health problem. Selenoprotien p1 (SEPP1) is widely acknowledged to be among the most delicate functional indicators of Se status and it plays a role in the metabolism of Se and in anti-oxidative defense. So, we aimed to assess Selenoprotein-p level in obese children and adolescents. Methods: This cross-sectional comparative work included 60 children: 30 obese children and the control group consisted of 30 children who were healthy and matched in terms of gender and age. A comprehensive taking of history and clinical assessment with anthropometric measurements were conducted on all children and adolescents. Basic investigations and serum selenoprotien-p1 level were performed. Results: Serum selenoprotien-p1 (SEPP1) levels were substantially decreased in obese children contrasted to controls. Conclusions: Selenoprotien p1 levels were substantially decreased in obese children and adolescent. Selenoprotien p1 could be a sensitive functional biomarker of selenium status.

show abstract

Section: Discussionmentioning

confidence: 87%

Selenoprotein-p as Biomarker of Selenium Status in Obese Children and Adolescents

Mahmoud,

Elshafiey,

Elsharaby

et al. 2023

AJPR

View full text Add to dashboard Cite

show abstract

“…On the other hand, the role of SPX in the metabolism of a 3-year-old child may be slightly different, although there may also be potential similarities between the roles of SPX in fetal and infancy. One such similarity is the protective role of SPX on cardiomyocyte metabolism [ 42 ], since SPX, as mentioned above, can also play a role in infancy (development of heart cells). In addition, up to 36 months of age, adipose tissue develops, and the greater amount of brown adipose tissue that was present in the newborn is replaced by white adipose tissue.…”

Section: Discussionmentioning

confidence: 99%

Cord Blood Spexin Level in Mothers with Obesity—Forecast of Future Obesity?

Wojciechowska,

Kolodziejski,

Pruszynska-Oszmalek

et al. 2023

Children

View full text Add to dashboard Cite

Spexin (SPX) is a peptide that plays an important role in the regulation of food intake and body weight (BW) by the effect on carbohydrate-lipid metabolism. However, the role of SPX in fetal life, in children, and in adolescent metabolism is limited. Therefore, we decided to check whether obesity affects the concentration of SPX in the mother’s peripheral blood (MB) and umbilical cord blood (UCB). Using MB and UCB sera on the day of delivery obtained from 48 women (24 non-obese and 24 obese) and commercially available Elisa kits and colorimetric assays, we determined changes in SPX and the relationship between SPX concentration and other metabolic and anthropometric markers (body weight and BMI) on the day of delivery and in children at the age of 36 months. We found lower concentrations of SPX in MB (p < 0.05) and UCB (p < 0.01) derived from obese women (BMI > 30) and a moderate linear correlation (r = 0.4429; p < 0.01) between SPX concentrations in MB and UCB. We also noted that the concentration of SPX is not correlated with the child’s body weight on the day of birth (r = −0.0128). However, there is a relationship between SPX at birth and body weight at 3 years of age (r = −0.3219; p < 0.05). Based on the obtained results, it can be assumed that spexin is one of the factors modulating the child’s metabolism already in the fetal period and can be considered a potential marker of future predisposition to obesity. However, confirmation of this thesis requires additional research.

show abstract

“…33,43 In a study performed in obese children, low SPX levels were connected with vasculopathy independent of age and lipid profile. 52 Interestingly, serum SPX levels were found to be positively correlated with lipoprotein (a) in women. 53 Overall, there are limited studies on the effect of SPX on cardiac functions, but the effect of this peptide on the lipid profile should be considered as a treatment option for CVDs in the future.…”

Section: Cvd and Spxmentioning

confidence: 97%

Impact of spexin on metabolic diseases and inflammation: An updated minireview

Türkel

Memi

Yazgan

2022

Exp Biol Med (Maywood)

View full text Add to dashboard Cite

Spexin (SPX) is a 14 amino acid length peptide hormone which was discovered using bioinformatic tools. It is extensively expressed in central and peripheral tissues and secreted into circulation in response to metabolic stress. Recent studies revealed that SPX acts as a multifunctional peptide in various metabolic processes such as body weight, food intake, energy balance, glucose and lipid metabolism, lipid storage, salt–water balance, and arterial blood pressure. Endogenous SPX is sensitive to metabolic changes, and circulating levels of SPX have been shown to be reduced in chronic diseases such as obesity, diabetes, and insulin resistance. Moreover, in fish and rodent models, systemic SPX treatment has positive effects on metabolism including reduced food intake, fat mass, lipid accumulation, and inflammation, improved insulin sensitivity, energy expenditure, and organ functions which are underlying mechanisms in diseases. Taken together, these findings suggest that SPX is a potential drug target for the development of new pharmacological strategies to cure metabolic diseases. This review focuses on metabolo-protective properties of SPX and discusses novel insights into the biology and mechanism of SPX in the pathogenesis of diabetes, obesity, non-alcoholic fatty liver disease, metabolic syndrome, polycystic ovary syndrome, cardiovascular diseases, and kidney diseases, which are considerable global health problems.

show abstract

Circulating spexins in children with obesity: relation to cardiometabolic risk

Cited by 4 publications

References 31 publications

Selenoprotein-p as Biomarker of Selenium Status in Obese Children and Adolescents

Selenoprotein-p as Biomarker of Selenium Status in Obese Children and Adolescents

Cord Blood Spexin Level in Mothers with Obesity—Forecast of Future Obesity?

Impact of spexin on metabolic diseases and inflammation: An updated minireview

Contact Info

Product

Resources

About